1545-5017/asset/MPO_centre.gif?v=1&s=8c0b4c386f6ece3ce7f8c5c02144983ee96bc8b6)
Brief Report
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia
Article first published online: 7 FEB 2009
DOI: 10.1002/pbc.21938
Copyright © 2009 Wiley-Liss, Inc.
Additional Information
How to Cite
Millot, F., Cividin, M., Brizard, F., Chomel, J. C., Méchinaud, F. and Guilhot, F. (2009), Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. Pediatric Blood & Cancer, 52: 891–892. doi: 10.1002/pbc.21938
Publication History
- Issue published online: 7 APR 2009
- Article first published online: 7 FEB 2009
- Manuscript Accepted: 16 DEC 2008
- Manuscript Received: 10 OCT 2008
- Abstract
- Article
- References
- Cited By
Keywords:
- acute lymphoblastic leukemia;
- dasatinib;
- Philadelphia chromosome;
- tyrosine kinase inhibitors
Abstract
We report on the use of dasatinib, a second-generation bcr-abl kinase inhibitor, in a child in early relapse of Philadelphia chromosome positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation. This patient benefited from the use of dasatinib obtaining of a complete molecular response which allowed a second successful transplant. Moreover, dasatinib was well tolerated in this heavily pretreated patient. Pediatr Blood Cancer 2009;52:891–892. © 2009 Wiley-Liss, Inc.